159 related articles for article (PubMed ID: 11416219)
1. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
Yang XF; Wu CJ; McLaughlin S; Chillemi A; Wang KS; Canning C; Alyea EP; Kantoff P; Soiffer RJ; Dranoff G; Ritz J
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7492-7. PubMed ID: 11416219
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
Wu CJ; Biernacki M; Kutok JL; Rogers S; Chen L; Yang XF; Soiffer RJ; Ritz J
Clin Cancer Res; 2005 Jun; 11(12):4504-11. PubMed ID: 15958636
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
Zhang W; Choi J; Zeng W; Rogers SA; Alyea EP; Rheinwald JG; Canning CM; Brusic V; Sasada T; Reinherz EL; Ritz J; Soiffer RJ; Wu CJ
Clin Cancer Res; 2010 May; 16(10):2729-39. PubMed ID: 20460482
[TBL] [Abstract][Full Text] [Related]
4. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.
Yang XF; Wu CJ; Chen L; Alyea EP; Canning C; Kantoff P; Soiffer RJ; Dranoff G; Ritz J
Cancer Res; 2002 Oct; 62(19):5517-5522. PubMed ID: 12359762
[TBL] [Abstract][Full Text] [Related]
5. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.
Wu CJ; Yang XF; McLaughlin S; Neuberg D; Canning C; Stein B; Alyea EP; Soiffer RJ; Dranoff G; Ritz J
J Clin Invest; 2000 Sep; 106(5):705-14. PubMed ID: 10974024
[TBL] [Abstract][Full Text] [Related]
6. A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
Yan Y; Phan L; Yang F; Talpaz M; Yang Y; Xiong Z; Ng B; Timchenko NA; Wu CJ; Ritz J; Wang H; Yang XF
J Immunol; 2004 Jan; 172(1):651-60. PubMed ID: 14688378
[TBL] [Abstract][Full Text] [Related]
7. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Schmitt A; Kirchner D; Krähn G; Heilmann V; Gschwend J; Bergmann L; Döhner H; Schmitt M
Exp Hematol; 2002 Sep; 30(9):1029-35. PubMed ID: 12225794
[TBL] [Abstract][Full Text] [Related]
8. Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Hasegawa H; Yasukawa M
Cancer Sci; 2008 Jul; 99(7):1414-9. PubMed ID: 18422754
[TBL] [Abstract][Full Text] [Related]
9. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
10. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
11. Humoral immune responses to testis antigens in sera from patients with prostate cancer.
Hoeppner LH; Dubovsky JA; Dunphy EJ; McNeel DG
Cancer Immun; 2006 Jan; 6():1. PubMed ID: 16401063
[TBL] [Abstract][Full Text] [Related]
12. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia.
Greiner J; Ringhoffer M; Taniguchi M; Hauser T; Schmitt A; Döhner H; Schmitt M
Int J Cancer; 2003 Aug; 106(2):224-31. PubMed ID: 12800198
[TBL] [Abstract][Full Text] [Related]
13. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.
Biernacki MA; Marina O; Zhang W; Liu F; Bruns I; Cai A; Neuberg D; Canning CM; Alyea EP; Soiffer RJ; Brusic V; Ritz J; Wu CJ
Cancer Res; 2010 Feb; 70(3):906-15. PubMed ID: 20103624
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of antibodies against proteins derived from leukemia cells in patients with chronic myeloid leukemia.
Ling M; Wen YJ; Lim SH
Blood; 1998 Dec; 92(12):4764-70. PubMed ID: 9845543
[TBL] [Abstract][Full Text] [Related]
15. Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients.
Takahashi H; Furukawa T; Yano T; Sato N; Takizawa J; Kurasaki T; Abe T; Narita M; Masuko M; Koyama S; Toba K; Takahashi M; Aizawa Y
Exp Hematol; 2007 Jul; 35(7):1091-9. PubMed ID: 17588478
[TBL] [Abstract][Full Text] [Related]
16. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies.
Wang Z; Zhang Y; Liu H; Salati E; Chiriva-Internati M; Lim SH
Blood; 2003 Feb; 101(3):955-60. PubMed ID: 12393489
[TBL] [Abstract][Full Text] [Related]
17. [Cloning, prokaryotic expression of CML66 and preparation of its polyclonal antibody].
You Q; Cheng LL; Wang Y; Wang SJ; Zhang HZ; Ge HL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Nov; 19(6):582-4. PubMed ID: 15182656
[TBL] [Abstract][Full Text] [Related]
18. Antigens recognized by autologous antibody in patients with renal-cell carcinoma.
Scanlan MJ; Gordan JD; Williamson B; Stockert E; Bander NH; Jongeneel V; Gure AO; Jäger D; Jäger E; Knuth A; Chen YT; Old LJ
Int J Cancer; 1999 Nov; 83(4):456-64. PubMed ID: 10508479
[TBL] [Abstract][Full Text] [Related]
19. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.
Dubovsky JA; McNeel DG; Powers JJ; Gordon J; Sotomayor EM; Pinilla-Ibarz JA
Clin Cancer Res; 2009 May; 15(10):3406-15. PubMed ID: 19401350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
